Home  |  Contact

UniProtKB/Swiss-Prot P62873: Variant p.Leu95Pro

Guanine nucleotide-binding protein G(I)/G(S)/G(T) subunit beta-1
Gene: GNB1
Chromosomal location: 1pter-p31.2
Variant information

Variant position:  95
The position of the amino-acid change on the UniProtKB canonical protein sequence.

Type of variant:  Disease [Disclaimer]
The variants are classified into three categories: Disease, Polymorphism and Unclassified.
  • Disease: Variants implicated in disease according to literature reports.
  • Polymorphism: Variants not reported to be implicated in disease.
  • Unclassified: Variants with uncertain implication in disease according to literature reports. Evidence against or in favor of a pathogenic role is limited and/or conflicting.

Residue change:  From Leucine (L) to Proline (P) at position 95 (L95P, p.Leu95Pro).
Indicates the amino acid change of the variant. The one-letter and three-letter codes for amino acids used in UniProtKB/Swiss-Prot are those adopted by the commission on Biochemical Nomenclature of the IUPAC-IUB.

Physico-chemical properties:  Similar physico-chemical property. Both residues are medium size and hydrophobic.
The physico-chemical property of the reference and variant residues and the change implicated.

BLOSUM score:  -3
The score within a Blosum matrix for the corresponding wild-type to variant amino acid change. The log-odds score measures the logarithm for the ratio of the likelihood of two amino acids appearing by chance. The Blosum62 substitution matrix is used. This substitution matrix contains scores for all possible exchanges of one amino acid with another:
  • Lowest score: -4 (low probability of substitution).
  • Highest score: 11 (high probability of substitution).
More information can be found on the following page

Involvement in disease:  Mental retardation, autosomal dominant 42 (MRD42) [MIM:616973]: A form of mental retardation, a disorder characterized by significantly below average general intellectual functioning associated with impairments in adaptive behavior and manifested during the developmental period. MRD42 patients manifest global developmental delay commonly accompanied by hypotonia, seizures of various types, ophthalmological manifestations, and poor growth. {ECO:0000269|PubMed:25485910, ECO:0000269|PubMed:27108799, ECO:0000269|PubMed:27668284, ECO:0000269|PubMed:28087732}. Note=The disease is caused by mutations affecting the gene represented in this entry.
The name and a short description of the disease associated with the variant. For more information about the disease, the user can refer to OMIM, following the link provided after the disease acronym.

Variant description:  In MRD42.
Any additional useful information about the variant.

Other resources:  
Links to websites of interest for the variant.



Sequence information

Variant position:  95
The position of the amino-acid change on the UniProtKB canonical protein sequence.

Protein sequence length:  340
The length of the canonical sequence.

Location on the sequence:   QDGKLIIWDSYTTNKVHAIP  L RSSWVMTCAYAPSGNYVACG
The residue change on the sequence. Unless the variant is located at the beginning or at the end of the protein sequence, both residues upstream (20) and downstream (20) of the variant will be shown.

Sequence annotation in neighborhood:  
The regions or sites of interest surrounding the variant. In general the features listed are posttranslational modifications, binding sites, enzyme active sites, local secondary structure or other characteristics reported in the cited references. The "Sequence annotation in neighborhood" lines have a fixed format:
  • Type: the type of sequence feature.
  • Positions: endpoints of the sequence feature.
  • Description: contains additional information about the feature.

TypePositionsDescription
Chain 2 – 340 Guanine nucleotide-binding protein G(I)/G(S)/G(T) subunit beta-1
Repeat 95 – 125 WD 2


Literature citations

Germline de novo mutations in GNB1 cause severe neurodevelopmental disability, hypotonia, and seizures.
Petrovski S.; Kuery S.; Myers C.T.; Anyane-Yeboa K.; Cogne B.; Bialer M.; Xia F.; Hemati P.; Riviello J.; Mehaffey M.; Besnard T.; Becraft E.; Wadley A.; Politi A.R.; Colombo S.; Zhu X.; Ren Z.; Andrews I.; Dudding-Byth T.; Schneider A.L.; Wallace G.; Rosen A.B.; Schelley S.; Enns G.M.; Corre P.; Dalton J.; Mercier S.; Latypova X.; Schmitt S.; Guzman E.; Moore C.; Bier L.; Heinzen E.L.; Karachunski P.; Shur N.; Grebe T.; Basinger A.; Nguyen J.M.; Bezieau S.; Wierenga K.; Bernstein J.A.; Scheffer I.E.; Rosenfeld J.A.; Mefford H.C.; Isidor B.; Goldstein D.B.;
Am. J. Hum. Genet. 98:1001-1010(2016)
Cited for: INVOLVEMENT IN MRD42; VARIANTS MRD42 GLU-76; GLY-76; SER-77; ARG-78; ASN-80; THR-80; PRO-95; VAL-101 AND THR-326;

Disclaimer: Any medical or genetic information present in this entry is provided for research, educational and informational purposes only. They are not in any way intended to be used as a substitute for professional medical advice, diagnostic, treatment or care.